Why PRP Doesn’t Work The Same For Everyone

Dr. Rakshitha Jayaprakash, MD

Dermatologist & Founder of Legacy – Concierge Medicine

• Focused on aesthetic dermatology, regenerative medicine, and holistic longevity science.
• Quantifying inflammatory and metabolic signals across dermatological presentations

Dr. Rakshitha Jayaprakash is a future-focused MD dedicated to the intersection of science-backed beauty and systemic health. Moving beyond traditional “quick fixes,” she specializes in Regenerative Aesthetics, focusing on how to biologically optimize the skin for long-term vitality rather than just temporary change.

Her clinical philosophy centers on the belief that a natural glow is the result of living optimally. By prioritizing longevity and cellular health, Dr. Rakshitha helps patients move away from transactional treatments toward comprehensive anti-aging solutions that empower the skin to function and look younger.

https://www.instagram.com/dr.rakshitha.jayaprakash.md/

Variability in biological responsiveness across regenerative dermatology

Introduction

Platelet-rich plasma (PRP) is widely used across dermatology, particularly in androgenetic alopecia and aesthetic applications. Despite broadly similar preparation methods and delivery techniques, clinicians frequently observe marked variability in response between individuals.

In controlled settings, some patients demonstrate measurable changes within defined study periods, while others show limited or inconsistent response under comparable conditions.

This variability has led to increasing interest in whether differences in platelet composition, inflammatory signalling, and tissue microenvironment may influence how PRP-derived signals are interpreted at a cellular level.

Background: PRP as a Biological Input

PRP is an autologous concentrate derived from whole blood, containing:

• Platelets
• Growth factors (e.g., platelet-derived growth factor, vascular endothelial growth factor, transforming growth factor-beta)
• Cytokines and chemokines

Platelets act as signalling mediators, releasing factors involved in:

• Angiogenesis
• Cellular proliferation
• Extracellular matrix remodelling

However, PRP is not a uniform substance. Human studies have demonstrated:

• Up to 3–5 fold variability in platelet concentration between individuals
• Differences in growth factor release profiles
• Variability in leukocyte content depending on preparation methods

This suggests that PRP represents a variable biological input, even before considering patient-level differences.

Clinical Variability: Evidence from Human Studies

In studies evaluating PRP for androgenetic alopecia, variability in outcomes has been consistently reported.

For example:

• A randomised placebo-controlled study (n≈60) reported mean increases in hair density of approximately 15–30% following treatment, with wide variation between participants (Gentile et al., 2015)
• A double-blind, half-head study (n≈90) demonstrated statistically significant improvement compared to placebo, but with substantial inter-individual variability in magnitude of response (Alves & Grimalt, 2016)

Systematic reviews and meta-analyses have similarly highlighted:

• Significant heterogeneity across studies
• Variability within treatment groups
• Inconsistent reporting of responder and non-responder distributions

These findings indicate that mean outcomes may not adequately represent individual response patterns.

Inflammatory Context and Tissue Responsiveness

Emerging evidence suggests that the local and systemic inflammatory environment may influence how PRP-derived signals are processed.

Inflammatory cytokines such as IL-6 and TNF-α have been shown to:

• Alter intracellular signalling pathways
• Interfere with insulin receptor function (Hotamisligil, 2006)
• Influence fibroblast and keratinocyte activity

In hair biology, inflammatory signalling has been associated with:

• Disruption of the anagen (growth) phase
• Perifollicular inflammation and fibrosis
• Altered vascular support

These factors may contribute to differences in tissue responsiveness, although current evidence is largely associative and does not establish direct causality.

A Conceptual Framework: Signal Delivery vs Biological Responsiveness

Variability in PRP outcomes may be interpreted through a distinction between:

Signal Delivery

• Platelet concentration
• Growth factor availability
• Preparation-related variability

Biological Responsiveness

• Tissue receptivity
• Inflammatory tone
• Cellular signalling capacity

Within this framework, PRP provides a biological signal, but the observed effect may depend on how that signal is interpreted within the target tissue.

This may help explain why:

• Similar procedural inputs yield different outcomes
• Variability persists even under controlled study conditions

This model remains conceptual and is not yet standardised in clinical literature.

Observed Stratification in PRP Cohorts

Subgroup analyses within PRP studies have described variability in platelet concentration and associated biological responses.

In observational datasets:

• Higher platelet concentration groups (often exceeding ~4–5× baseline) have been associated with comparatively greater mean changes in hair density within study periods
• Intermediate concentration ranges (approximately 3–5× baseline) demonstrate moderate variability in observed outcomes
• Lower concentration ranges (<3× baseline), particularly when accompanied by elevated inflammatory markers, have been associated with reduced or inconsistent observable changes

Reported mean increases in hair density across studies range broadly from approximately 10% to 30%, with significant inter-individual variability within each subgroup (Gentile et al., 2015; Alves & Grimalt, 2016).

These findings are derived from cohort-level observations and remain non-standardised, with variability in preparation methods, measurement techniques, and study design.

Population and Biological Variability

Inter-individual variability in PRP response may also reflect broader biological differences.

Studies have reported:

• Variability in platelet function and activation between individuals
• Differences in baseline inflammatory markers across populations
• Higher prevalence of insulin resistance in certain ethnic groups

Studies involving South Asian cohorts have also described:

• Higher baseline platelet counts compared to some Western populations (reported differences of approximately 10–20%)
• Increased prevalence of insulin resistance, in some datasets up to 1.5–2 times higher at comparable BMI ranges

These factors may influence both the composition of PRP and the biological context in which it is applied, although their impact on observed outcomes remains incompletely defined.

Limitations and Evidence Gaps

Despite widespread use of PRP, several limitations persist:

• Heterogeneity in preparation methods
• Variability in platelet concentration and composition
• Lack of standardised outcome measures
• Limited reporting of responder versus non-responder distributions

Additionally:

• Many studies involve modest sample sizes
• Follow-up durations vary
• Mechanistic pathways remain incompletely defined

These limitations make it challenging to determine the precise contributors to response variability.

Professional Context

PRP is widely utilised within dermatology, yet its variability highlights broader challenges in regenerative medicine.

Rather than functioning as a uniform intervention, PRP may be better understood as a biological input interacting with a dynamic and variable tissue environment.

This perspective shifts attention from procedural consistency alone toward understanding variability in biological responsiveness, although consensus frameworks are still evolving.

Key Takeaway

Human studies demonstrate that PRP is associated with measurable changes in dermatological parameters, including increases in hair density. However, these effects show significant inter-individual variability, with reported mean changes ranging from approximately 10% to 30% across studies.

Variability in platelet concentration, inflammatory signalling, and tissue microenvironment may contribute to differences in observed outcomes. Current evidence supports associative relationships but does not establish predictive markers or standardised models of responsiveness.

References

• Gentile, P. et al. (2015) ‘The effect of platelet-rich plasma in hair regrowth: A randomized placebo-controlled trial’, Stem Cells Translational Medicine, 4(11), pp. 1317–1323.
• Alves, R. and Grimalt, R. (2016) ‘Randomized placebo-controlled, double-blind, half-head study to assess the efficacy of platelet-rich plasma in androgenetic alopecia’, Dermatologic Surgery, 42(4), pp. 491–497.
• Hotamisligil, G.S. (2006) ‘Inflammation and metabolic disorders’, Nature, 444(7121), pp. 860–867.
• Gupta, A.K. and Carviel, J. (2017) ‘A mechanistic model of platelet-rich plasma treatment for androgenetic alopecia’, Dermatologic Surgery, 43(10), pp. 1264–1273.

More by this Author

• Why Everything we’re Doing for Skin, Hair, and Weight May Not Translate Clinically
• Longevity vs. Quick Fixes: Why We Must Stop Selling ‘Units’ and Start Selling ‘Anti-Aging Solutions’